- Home
- VMD vs LUNG Comparison
VMD vs LUNG Comparison
Compare VMD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | LUNG |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.3M | 72.2M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VMD | LUNG |
|---|---|---|
| Price | $9.20 | $1.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 344.3K | ★ 711.1K |
| Earning Date | 03-04-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | 7.64 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $270,280,000.00 | $90,497,000.00 |
| Revenue This Year | $24.27 | $6.20 |
| Revenue Next Year | $15.47 | $21.61 |
| P/E Ratio | $23.54 | ★ N/A |
| Revenue Growth | ★ 20.52 | 8.01 |
| 52 Week Low | $5.93 | $1.31 |
| 52 Week High | $10.06 | $7.46 |
Technical Indicators
Market Signals| Indicator | VMD | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 36.92 |
| Support Level | $6.35 | N/A |
| Resistance Level | $10.06 | $1.93 |
| Average True Range (ATR) | 0.51 | 0.16 |
| MACD | -0.06 | -0.04 |
| Stochastic Oscillator | 63.50 | 1.18 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.